Study to assess whether Inhalational Bronchodilator given prior to bronchoscopy reduces discomfort due to breathlessness and cough

Effect of pre-bronchoscopy inhaled bronchodilator ( salbutamol ) on procedure related outcomes in patients with airway obstruction.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/04/003520

Enrollment

Registered

2013-04-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with any respiratory disease leading to FEV1/FVC less than 70%

Interventions

Intervention1: MDI Salbutamol ( metered dose inhaler containing drug-salbutamol ): Dose 400 micrograms( 4 Puffs) Duration single dose prior to bronchoscopy Frequency single dose of 4 puffs prior to br

Eligibility

Inclusion criteria

Inclusion criteria: â?¦ All patients undergoing fibreoptic bronchoscopy and having evidence of airway obstruction as assessed by spirometry i.e FEV1/FVC â?¦ Patients who give consent for the study

Exclusion criteria

Exclusion criteria: Those who are not willing to participate

Design outcomes

Primary

Measure	Time frame
ï?½ To determine whether use of inhaled bronchodilator prior to bronchoscopy provides a protective effect in patients with underlying airway obstruction. Timepoint: Pulmonary Function Test will be done within 2 hours post bronchoscopy.	—

Secondary

Measure	Time frame
To evaluate whether this intervention ( MDI salbutamol ) has any beneficial effect on procedure related outcomes.Timepoint: questionnaires will be filled by patient regarding symptoms before and after Bronchoscopy.	—

Countries

India

Contacts

Public ContactIndrajit G Momin

AIIMS, New Delhi

indrajitgmomin@yahoo.co.in9013860043

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026